We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LegoChem Biosciences

News List

CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate prnasia
October 29, 2020
CStone Pharmaceuticals announced today a licensing agreement with LegoChem Biosciences, Inc., for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate ("ADC").
LegoChem Biosciences, Iksuda collaborate to develop antibody-drug conjugates pharmaceutical-business-review
April 22, 2020
LegoChem Biosciences, based in Daejeon, South Korea, announced that it has entered a research collaboration and license agreement with Iksuda Therapeutics for the development of antibody-drug conjugates in oncology.
LegoChem Biosciences, Takeda collaborate for immuno-oncology research biospectrumasia
March 25, 2019
Takeda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology